Nonetheless, recent studies have revealed that HNSCC tumors exhibiting heightened levels of PD-L1 expression are more prone to react favorably to immunotherapy medications that directly aim at the PD-L1/PD-1 pathway [18]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.